


Sleep Apnea Severity with Tirzepatide vs Placebo in SURMOUNT-OSA Trials

People with OSA and Obesity



Safety

The overall safety profile of tirzepatide in SURMOUNT-OSA studies was similar to previously reported SURMOUNT and SURPASS trials

The most commonly reported adverse events in SURMOUNT-OSA studies were GI-related and generally mild to moderate in severity:

- SURMOUNT-OSA Study 1: diarrhea, nausea and vomiting
- SURMOUNT-OSA Study 2: diarrhea, nausea and constipation

*Tirzepatide MTD is maximum tolerated dose of 10 mg or 15 mg once-weekly. The starting dose of 2.5 mg tirzepatide was increased by 2.5 mg every four weeks until maximum tolerated dose was achieved. Participants who tolerated 15 mg continued on 15 mg as their maximum tolerated dose. Participants who tolerated 10 mg but did not tolerate 15 mg continued on 10 mg as their maximum tolerated dose.